(Q39730660)

20213120

14 September 2017

title

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

0 references

2

Hideo Yagita

1 reference

14 September 2017

Sujin Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

Thomas J Sayers

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

Esteban Celis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

Hideo Yagita

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

publication date

6 March 2010

1 reference

20213120

Cancer Immunology, Immunotherapy

14 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

page(s)

1073-1081

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-010-0834-0

14 May 2020

exact match

0 references

cites work

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00262-010-0834-0

A new therapy with bortezomib, an oncologic medicinal product of the year 2004

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00262-010-0834-0

A review of the proteasome inhibitor bortezomib in multiple myeloma

21 January 2018

1 reference

12 December 2020

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma

1 reference

12 December 2020

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors

1 reference

12 December 2020

Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.

1 reference

12 December 2020

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

1 reference

12 December 2020

Is TRAIL the holy grail of cancer therapy?

1 reference

12 December 2020

Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.

1 reference

12 December 2020

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody

1 reference

12 December 2020

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

1 reference

12 December 2020

CpG motifs in bacterial DNA and their immune effects

1 reference

12 December 2020

Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.

1 reference

12 December 2020

Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer

1 reference

12 December 2020

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

1 reference

12 December 2020

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

1 reference

12 December 2020

Apoptosis and cancer.

1 reference

12 December 2020

Eradication of established tumors in mice by a combination antibody-based therapy

1 reference

12 December 2020

Management of multiple myeloma with bortezomib: experts review the data and debate the issues

1 reference

12 December 2020

CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma

1 reference

12 December 2020

c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.

1 reference

12 December 2020

Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells

1 reference

12 December 2020

Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway

1 reference

12 December 2020

TRAIL-induced apoptosis: between tumor therapy and immunopathology

1 reference

12 December 2020

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

1 reference

12 December 2020

In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells

1 reference

12 December 2020

Functional aspects of apoptosis in hematopoiesis and consequences of failure

1 reference

12 December 2020

Apoptosis and cancer: the genesis of a research field

1 reference

12 December 2020

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis

1 reference

12 December 2020

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

1 reference

12 December 2020

Discovery, Development, and clinical applications of bortezomib

1 reference

12 December 2020

Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity

1 reference

12 December 2020

Sensitizing tumor cells to immune-mediated cytotoxicity

1 reference

12 December 2020

10.1007/S00262-010-0834-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

release_v3jfycd53zdddmfilohztjmbwy

14 May 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v3jfycd53zdddmfilohztjmbwy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993141&resulttype=core&format=json

14 May 2020

20213120

1 reference